drugset / Trial / NCT00274326

DILIPO (DILutIonal HyPOnatremia)

NCT00274326 ↗

Phase 3 Completed 150 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary: * To assess the efficacy of SR121463B in correcting hyponatremia in patients with dilutional hyponatremia other than SIADH or cirrhosis Secondary: * To assess the long-term efficacy of SR121463B in maintaining normonatremia in these patients * To assess the safety and tolerability of SR121463B

Timeline

Start
2005-05
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject satavaptan Small molecule 25 mg Oral
Subject satavaptan Small molecule 50 mg Oral